US20010041734A1 - Method of treating traumatic brain injury and other neuronal disorders - Google Patents
Method of treating traumatic brain injury and other neuronal disorders Download PDFInfo
- Publication number
- US20010041734A1 US20010041734A1 US09/886,206 US88620601A US2001041734A1 US 20010041734 A1 US20010041734 A1 US 20010041734A1 US 88620601 A US88620601 A US 88620601A US 2001041734 A1 US2001041734 A1 US 2001041734A1
- Authority
- US
- United States
- Prior art keywords
- nefiracetam
- brain injury
- traumatic brain
- effective amount
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NGHTXZCKLWZPGK-UHFFFAOYSA-N CC1=CC=CC(C)=C1NC(=O)CN1CCCC1=O Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCCC1=O NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- the present invention relates to a method for treatment of brain injury and neuronal disorders, such as epilepsy, by administration of an effective amount of nefiracetam.
- Cerebral concussion is a traumatically induced derangement of the nervous system, characterized clinically by immediate and transient impairment of consciousness and is generally not associated with remarkable gross anatomical changes. Even moderate levels of concussive human head injury, not requiring prolonged hospitalization, can result in persistent neurological disturbances often lasting for months. These disturbances often include dizziness and balance problems, and fine motor skill dysfunction. Lyeth et al, Brain Research, 452, 39-48 (1988).
- Traumatic brain injury is known to be a biphasic process.
- the first phase, the excitatory phase, occurs immediately upon injury. During this phase there is great neuronal excitation due to the trauma.
- the recovery phase Following the excitatory phase is the recovery phase, during which the neuronal excitation has abated and the job of repair has begun.
- the excitatory phase is associated with increased intracranial pressure (ICP), with fluctuations of ICP over several days or more.
- ICP intracranial pressure
- Patients in the excitatory phase must typically be cared for in the intensive care unit of a hospital. Once the ICP has been stabilized and the patient can be removed from intensive care, the patient is typically entering into the recovery phase.
- antagonists of these cholinergic or glutamatergic receptors such as the AMPA-glutamate receptor, wherein AMPA represents ⁇ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
- one object of the present invention is to provide a method effective for the treatment of brain injuries, particularly traumatic brain injury.
- a further object of the present invention is to provide a method for treatment of neuronal disorders such as epilepsy.
- FIG. 1 is a graphical presentation of test data on brain injured rats showing the improvement in performance achieved using the present method compared to a control group.
- the present invention relates to a method for the treatment of neuronal disorders and brain injury which comprises administering to a subject in need thereof, an effective amount of nefiracetam.
- nefiracetam administration of nefiracetam to a subject that has suffered a neuronal disorder or a traumatic brain injury, can provide dramatic improvements in brain function.
- An important factor in the present method is to administer nefiracetam as soon as possible after the excitatory phase of the injury process has ceased and the patient has entered into the recovery phase. If nefiracetam is administered too early, during the excitatory phase, the injury to the patient can actually be increased. However, if nefiracetam is administered during the period between entry into the recovery phase and the time at which the injury becomes permanent, the administration of nefiracetam can be highly effective at improving the recovery process and restoring significant levels of brain function.
- the present method can use nefiracetam or one or more of its metabolites.
- use of the term nefiracetam includes the possible use of one or more metabolites.
- the metabolites will have different chemical structures and different dosage levels, which are easily determinable by those of skill in the art.
- Nefiracetam N-(2,6-dimethyl-phenyl)-2(2-oxo-1-pyrrolidinyl) acetamide
- the nefiracetam can be administered neat or as a composition comprising nefiracetam and a pharmacologically acceptable carrier. Suitable carriers include water, saline and other conventionally used pharmacological carriers.
- the composition comprises from 0.1 to 100% of nefiracetam.
- the concentration of nefiracetam in the composition can be adjusted as desired to achieve a manageable dosage volume to provide any desired non-lethal dosage, preferably from 1 mg/kg to 30 mg/kg, more preferably from 5 mg/kg to 15 mg/kg, most preferably about 9 mg/kg per oral.
- nefiracetam can be administered in any orally or IV administrable form, such as tablets, troches, powders, emulsions, solutions, etc.
- the administration of nefiracetam should preferably begin as quickly as possible after the patient enters the recovery phase of the injury process or as soon as possible after the neuronal disorder is detected. Ideally, administration should begin no later than 1.5-2 weeks after entry into the recovery phase, most preferably no later than 1 week after entry into the recovery phase.
- the excitatory phase is characterized most often by fluctuations in ICP, during which the patient is typically placed in the intensive care unit of a hospital. Once the ICP has stabilized and the patient can be moved from the intensive care unit, the recovery phase is considered to be entered.
- the composition should be administered daily, with from 1 to 4 dosages per day. Improvements can typically be seen in the subject's brain function within about 2 weeks, although longer treatments can provide further improvement. Chronic administration, even up to lifetime administration, can be performed if desired.
- FIG. 1 shows the results achieved in rats using the method of the present invention.
- administration of nefiracetam at 3 mg/kg and 9 mg/kg were tested against a control group treated only with the pharmacological carrier (9% saline).
- the rats were subjected to a central fluid percussion injury, which is a typical animal model for traumatic brain injury. Beginning one day after the injury, the rats were subjected to daily oral drug administrations at the 3 and 9 mg/kg dosage levels.
- the administration solutions contained the nefiracetam in 9% saline at a concentration sufficient to provide the required dosage level in a single 1 ml/kg dosage of solution.
- the rats were then tested in the Morris water maze on days 11-15 after injury.
- the rats at the 9 mg/kg dosage level shows significant improvement in brain function as measured by performance in the water maze as compared to the control and the 3 mg/kg dosage level rats.
- the improvement seen at the 9 mg/kg dosage correlates to a reduction in the cognitive deficit by 55% compared to the control.
- the 3 mg/kg dosage level was not significantly effective.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
- 1. Field of the Invention
- The present invention relates to a method for treatment of brain injury and neuronal disorders, such as epilepsy, by administration of an effective amount of nefiracetam.
- 2. Discussion of the Background
- Traumatic brain injury, as well as neuronal disorders with common pathological features, such as stroke and epilepsy, can have devastating effects on a person, both short-term and long-term. Traumatic brain injury is often associated with cerebral concussion.
- Cerebral concussion is a traumatically induced derangement of the nervous system, characterized clinically by immediate and transient impairment of consciousness and is generally not associated with remarkable gross anatomical changes. Even moderate levels of concussive human head injury, not requiring prolonged hospitalization, can result in persistent neurological disturbances often lasting for months. These disturbances often include dizziness and balance problems, and fine motor skill dysfunction. Lyeth et al,Brain Research, 452, 39-48 (1988).
- Traumatic brain injury is known to be a biphasic process. The first phase, the excitatory phase, occurs immediately upon injury. During this phase there is great neuronal excitation due to the trauma. Following the excitatory phase is the recovery phase, during which the neuronal excitation has abated and the job of repair has begun. Most often with traumatic brain injury, the excitatory phase is associated with increased intracranial pressure (ICP), with fluctuations of ICP over several days or more. Patients in the excitatory phase must typically be cared for in the intensive care unit of a hospital. Once the ICP has been stabilized and the patient can be removed from intensive care, the patient is typically entering into the recovery phase.
- Traumatic brain injury produces an acute neuronal depolarization and an extensive release of neurotransmitters. The resulting excessive receptor activation may produce abnormal neurotransmitter-receptor interactions which contribute to the pathophysiology associated with experimental traumatic brain injury. Both the cholinergic and glutamatergic receptor systems have been documented to play a prominent role in the receptor-mediated pathophysiology of traumatic brain injury. Prior attempts to treat traumatic brain injury have focused on administration of antagonists of these cholinergic or glutamatergic receptors (such as the AMPA-glutamate receptor, wherein AMPA represents α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) as early as possible after the occurrence of the injury. (See Hamm et al,Cognitive Brain Research, 1, 223-226 (1993) and Lyeth et al, Brain Research, 452, 39-48 (1988)). The goal of these studies was to add the antagonist during the excitatory phase of the injury process during the period of high receptor activity in an attempt to minimize the damage occurring to the neuronal tissue. Unfortunately, such attempts were not successful.
- Accordingly, one object of the present invention is to provide a method effective for the treatment of brain injuries, particularly traumatic brain injury.
- A further object of the present invention is to provide a method for treatment of neuronal disorders such as epilepsy.
- These and other objects of the present invention have been satisfied by the discovery of a method for the treatment of neuronal disorders and brain injury comprising:
- administering to a subject in need thereof, an effective amount of nefiracetam.
- A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein;
- FIG. 1 is a graphical presentation of test data on brain injured rats showing the improvement in performance achieved using the present method compared to a control group.
- The present invention relates to a method for the treatment of neuronal disorders and brain injury which comprises administering to a subject in need thereof, an effective amount of nefiracetam.
- The present inventors have found that administration of nefiracetam to a subject that has suffered a neuronal disorder or a traumatic brain injury, can provide dramatic improvements in brain function. An important factor in the present method is to administer nefiracetam as soon as possible after the excitatory phase of the injury process has ceased and the patient has entered into the recovery phase. If nefiracetam is administered too early, during the excitatory phase, the injury to the patient can actually be increased. However, if nefiracetam is administered during the period between entry into the recovery phase and the time at which the injury becomes permanent, the administration of nefiracetam can be highly effective at improving the recovery process and restoring significant levels of brain function.
- The present method can use nefiracetam or one or more of its metabolites. Within the context of the present text, use of the term nefiracetam includes the possible use of one or more metabolites. Of course, the metabolites will have different chemical structures and different dosage levels, which are easily determinable by those of skill in the art. Nefiracetam (N-(2,6-dimethyl-phenyl)-2(2-oxo-1-pyrrolidinyl) acetamide) is a drug having the structure:
- It has previously been used as a nootropic drug in the treatment of senile dementia and Alzheimer's disease. An excellent review of the use of nefiracetam in such treatment is found in Yamada et al,CNS Drug Reviews, 2, 322-342 (1996), which is hereby incorporated by reference.
- The nefiracetam can be administered neat or as a composition comprising nefiracetam and a pharmacologically acceptable carrier. Suitable carriers include water, saline and other conventionally used pharmacological carriers. The composition comprises from 0.1 to 100% of nefiracetam. The concentration of nefiracetam in the composition can be adjusted as desired to achieve a manageable dosage volume to provide any desired non-lethal dosage, preferably from 1 mg/kg to 30 mg/kg, more preferably from 5 mg/kg to 15 mg/kg, most preferably about 9 mg/kg per oral. Alternatively, nefiracetam can be administered in any orally or IV administrable form, such as tablets, troches, powders, emulsions, solutions, etc.
- The administration of nefiracetam should preferably begin as quickly as possible after the patient enters the recovery phase of the injury process or as soon as possible after the neuronal disorder is detected. Ideally, administration should begin no later than 1.5-2 weeks after entry into the recovery phase, most preferably no later than 1 week after entry into the recovery phase. The excitatory phase is characterized most often by fluctuations in ICP, during which the patient is typically placed in the intensive care unit of a hospital. Once the ICP has stabilized and the patient can be moved from the intensive care unit, the recovery phase is considered to be entered.
- Preferably, the composition should be administered daily, with from 1 to 4 dosages per day. Improvements can typically be seen in the subject's brain function within about 2 weeks, although longer treatments can provide further improvement. Chronic administration, even up to lifetime administration, can be performed if desired.
- FIG. 1, shows the results achieved in rats using the method of the present invention. As shown in the graph, administration of nefiracetam at 3 mg/kg and 9 mg/kg were tested against a control group treated only with the pharmacological carrier (9% saline). The rats were subjected to a central fluid percussion injury, which is a typical animal model for traumatic brain injury. Beginning one day after the injury, the rats were subjected to daily oral drug administrations at the 3 and 9 mg/kg dosage levels. The administration solutions contained the nefiracetam in 9% saline at a concentration sufficient to provide the required dosage level in a single 1 ml/kg dosage of solution. The rats were then tested in the Morris water maze on days 11-15 after injury. On the days that the rats were tested, the drug was administered 15 minutes prior to testing. The rats at the 9 mg/kg dosage level shows significant improvement in brain function as measured by performance in the water maze as compared to the control and the 3 mg/kg dosage level rats. The improvement seen at the 9 mg/kg dosage correlates to a reduction in the cognitive deficit by 55% compared to the control. The 3 mg/kg dosage level was not significantly effective.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/886,206 US6420416B2 (en) | 2000-04-11 | 2001-06-22 | Method of treating epilepsy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/547,226 US6348489B1 (en) | 2000-04-11 | 2000-04-11 | Method of treating traumatic brain injury and other neuronal disorders |
US09/886,206 US6420416B2 (en) | 2000-04-11 | 2001-06-22 | Method of treating epilepsy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/547,226 Division US6348489B1 (en) | 2000-04-11 | 2000-04-11 | Method of treating traumatic brain injury and other neuronal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010041734A1 true US20010041734A1 (en) | 2001-11-15 |
US6420416B2 US6420416B2 (en) | 2002-07-16 |
Family
ID=24183833
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/547,226 Expired - Fee Related US6348489B1 (en) | 2000-04-11 | 2000-04-11 | Method of treating traumatic brain injury and other neuronal disorders |
US09/886,206 Expired - Fee Related US6420416B2 (en) | 2000-04-11 | 2001-06-22 | Method of treating epilepsy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/547,226 Expired - Fee Related US6348489B1 (en) | 2000-04-11 | 2000-04-11 | Method of treating traumatic brain injury and other neuronal disorders |
Country Status (5)
Country | Link |
---|---|
US (2) | US6348489B1 (en) |
EP (1) | EP1274423A4 (en) |
JP (1) | JP2003530350A (en) |
AU (1) | AU4687501A (en) |
WO (1) | WO2001076596A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011048208A1 (en) | 2009-10-22 | 2011-04-28 | University College Dublin, National University Of Ireland, Dublin | Causal therapy of diseases or conditions associated with cns or pns demyelination |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
EP2135611A1 (en) | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
WO2004019953A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2924011C2 (en) * | 1979-06-13 | 1982-04-08 | A. Nattermann & Cie GmbH, 5000 Köln | Pyrrolidin- (2) -one- (1) -ylacetic acid-2,6, -dimethylanilide, process for the preparation and medicaments containing this compound |
CA2067614C (en) * | 1991-05-02 | 2002-07-30 | Eiichi Otomo | Agent for improving dementia |
US5461157A (en) * | 1992-06-19 | 1995-10-24 | Daiichi Pharmaceutical Co., Ltd. | Process for preparing pyrrolidinylacetamide derivatives |
US6107330A (en) * | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
JPH1180027A (en) * | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | Intellect activator |
TW544311B (en) | 1998-08-06 | 2003-08-01 | Daiichi Seiyaku Co | Therapeutic or preventive agent for intractable epilepsies |
WO2000072844A1 (en) * | 1999-05-31 | 2000-12-07 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
-
2000
- 2000-04-11 US US09/547,226 patent/US6348489B1/en not_active Expired - Fee Related
-
2001
- 2001-04-10 WO PCT/JP2001/003073 patent/WO2001076596A1/en active Application Filing
- 2001-04-10 AU AU46875/01A patent/AU4687501A/en not_active Abandoned
- 2001-04-10 EP EP01919857A patent/EP1274423A4/en not_active Withdrawn
- 2001-04-10 JP JP2001574114A patent/JP2003530350A/en active Pending
- 2001-06-22 US US09/886,206 patent/US6420416B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011048208A1 (en) | 2009-10-22 | 2011-04-28 | University College Dublin, National University Of Ireland, Dublin | Causal therapy of diseases or conditions associated with cns or pns demyelination |
Also Published As
Publication number | Publication date |
---|---|
AU4687501A (en) | 2001-10-23 |
EP1274423A1 (en) | 2003-01-15 |
US6420416B2 (en) | 2002-07-16 |
WO2001076596A1 (en) | 2001-10-18 |
JP2003530350A (en) | 2003-10-14 |
EP1274423A4 (en) | 2006-09-06 |
US6348489B1 (en) | 2002-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4249415B2 (en) | Pyrrolidineacetamide derivatives alone or in combination for the treatment of CNS diseases | |
Cunningham et al. | A comparison of venlafaxine, trazodone, and placebo in major depression | |
US6489350B1 (en) | Methods for treating neuropathic pain using heteroarylmethanesulfonamides | |
Calcutt et al. | Spinal pharmacology of tactile allodynia in diabetic rats | |
Pertovaara et al. | Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective α2‐adrenoceptor antagonist | |
US5728728A (en) | Methods of providing neuroprotection | |
DE60101265T2 (en) | TREATMENT OF EYE PAIN | |
US4988710A (en) | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins | |
HUE026484T2 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
Hayes et al. | Possible protective effect of endogenous opioids in traumatic brain injury | |
US20160158166A1 (en) | Methods of reducing brain cell apoptosis | |
Müller et al. | Intrathecal baclofen in spasticity | |
WO2001013902A2 (en) | Combination of active agents, said combination containing clonidine and pramipexol | |
US6348489B1 (en) | Method of treating traumatic brain injury and other neuronal disorders | |
US6436937B1 (en) | Use of desoxypeganine in the treatment of Alzheimer's dementia | |
JP2001500113A (en) | How to treat mental retardation | |
Katsunuma et al. | Enhanced angiotensin-mediated responses in the nucleus tractus solitarii of spontaneously hypertensive rats | |
DE10318714B4 (en) | Drug combinations and therapies to combat alcohol abuse | |
EP3967308A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
Shinozaki et al. | Depression of decerebrate rigidity in the rat by antagonists of excitatory amino acids | |
Steiner et al. | α-Ethyltryptamine (etryptamine): An electroencephalographic, behavioral and neurochemical analysis | |
US5834497A (en) | Use of felodipine to treat cerebral dysfunction due to solvent exposure | |
CN1105560C (en) | Use of efaroxan for producing medicine for treating huntington disease | |
JP2000516213A (en) | How to treat catastrophic behavioral disorders | |
DE69816790T2 (en) | IMPROVING OPIOID TOLERANCE BY INHIBITING THE INDUCIBLE NITROGEN OXIDE SYNTHASE FOR TREATING PAIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DAIICHI PHARMACEUTICAL CO., LTD.;REEL/FRAME:016153/0466 Effective date: 20041213 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R1551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100716 |